{"ModuleTitle": "Company Description", "CompanyName": "Arena Pharmaceuticals, Inc.", "Symbol": "ARNA", "Address": "6154 NANCY RIDGE DRIVE, SAN DIEGO, California, 92121, United States of America", "Phone": "858-453-7200", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a biopharmaceutical company focused on delivering novel, transformational\r\nmedicines with optimized pharmacology and pharmacokinetics to patients globally.\r\nOur internally-developed pipeline includes multiple potentially first- or\r\nbest-in-class assets with broad clinical utility.\r\n\r\nOur most advanced investigational clinical programs include: etrasimod (APD334),\r\nbeing evaluated in a Phase 3 program for ulcerative colitis, or UC, a Phase 2b/3\r\nprogram for Crohn's disease, or CD, and a Phase 2b program in atopic dermatitis,\r\nor AD. We also plan to evaluate etrasimod in a Phase 2b program for eosinophilic\r\nesophagitis, or EOE, and a Phase 2 program in alopecia areata, or AA. Olorinab\r\n(APD371) is being evaluated for a broad range of visceral pain conditions\r\nassociated with gastrointestinal diseases and is currently in a Phase 2b trial\r\nfor treatment of abdominal pain associated with irritable bowel syndrome, or\r\nIBS.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f27%2f0001564590-20-007399.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Amit Dilip Munshi", "title": "President, Chief Executive Officer & Director"}, {"name": "Christopher H. Cabell", "title": "Chief Medical Officer, Head-Research & Development"}, {"name": "Douglas A. Bakan", "title": "Vice President-Technical Operations"}, {"name": "Laurie D. Stelzer", "title": "Chief Financial Officer & Executive Vice President"}, {"name": "Vincent E. Aurentz", "title": "Chief Business Officer & Executive Vice President"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}